Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 78


Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines.

Jaksch M, MĂșnera J, Bajpai R, Terskikh A, Oshima RG.

Cancer Res. 2008 Oct 1;68(19):7882-6. doi: 10.1158/0008-5472.CAN-08-0723.


The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation.

Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, Zeilstra J, Pals ST, Mehmet H, Stassi G, Medema JP.

Cancer Res. 2010 Jan 15;70(2):719-29. doi: 10.1158/0008-5472.CAN-09-1820. Epub 2010 Jan 12.


Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer.

Florek M, Haase M, Marzesco AM, Freund D, Ehninger G, Huttner WB, Corbeil D.

Cell Tissue Res. 2005 Jan;319(1):15-26. Epub 2004 Nov 19.


Expression of CD133 correlates with differentiation of human colon cancer cells.

Feng HL, Liu YQ, Yang LJ, Bian XC, Yang ZL, Gu B, Zhang H, Wang CJ, Su XL, Zhao XM.

Cancer Biol Ther. 2010 Feb;9(3):216-23. Epub 2010 Feb 16.


CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells.

Barrantes-Freer A, Renovanz M, Eich M, Braukmann A, Sprang B, Spirin P, Pardo LA, Giese A, Kim EL.

PLoS One. 2015 Jun 18;10(6):e0130519. doi: 10.1371/journal.pone.0130519. eCollection 2015.


Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis.

Botchkina IL, Rowehl RA, Rivadeneira DE, Karpeh MS Jr, Crawford H, Dufour A, Ju J, Wang Y, Leyfman Y, Botchkina GI.

Cancer Genomics Proteomics. 2009 Jan-Feb;6(1):19-29.


Copper-64-diacetyl-bis (N4-methylthiosemicarbazone) accumulates in rich regions of CD133+ highly tumorigenic cells in mouse colon carcinoma.

Yoshii Y, Furukawa T, Kiyono Y, Watanabe R, Waki A, Mori T, Yoshii H, Oh M, Asai T, Okazawa H, Welch MJ, Fujibayashi Y.

Nucl Med Biol. 2010 May;37(4):395-404. doi: 10.1016/j.nucmedbio.2009.12.011. Epub 2010 Feb 10.


Prospectively isolated cancer-associated CD10(+) fibroblasts have stronger interactions with CD133(+) colon cancer cells than with CD133(-) cancer cells.

Cui L, Ohuchida K, Mizumoto K, Moriyama T, Onimaru M, Nakata K, Nabae T, Ueki T, Sato N, Tominaga Y, Tanaka M.

PLoS One. 2010 Aug 12;5(8):e12121. doi: 10.1371/journal.pone.0012121.


CD133+CD44+ population efficiently enriches colon cancer initiating cells.

Haraguchi N, Ohkuma M, Sakashita H, Matsuzaki S, Tanaka F, Mimori K, Kamohara Y, Inoue H, Mori M.

Ann Surg Oncol. 2008 Oct;15(10):2927-33. doi: 10.1245/s10434-008-0074-0. Epub 2008 Jul 29.


CD133 induces tumour-initiating properties in HEK293 cells.

Canis M, Lechner A, Mack B, Zengel P, Laubender RP, Koehler U, Heissmeyer V, Gires O.

Tumour Biol. 2013 Feb;34(1):437-43. doi: 10.1007/s13277-012-0568-z. Epub 2012 Nov 13.


A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.

O'Brien CA, Pollett A, Gallinger S, Dick JE.

Nature. 2007 Jan 4;445(7123):106-10. Epub 2006 Nov 19.


The importance of the stem cell marker prominin-1/CD133 in the uptake of transferrin and in iron metabolism in human colon cancer Caco-2 cells.

Bourseau-Guilmain E, Griveau A, Benoit JP, Garcion E.

PLoS One. 2011;6(9):e25515. doi: 10.1371/journal.pone.0025515. Epub 2011 Sep 26.


Two novel monoclonal antibodies against human CD133-2: distinct epitopes and agonist activity to enhance growth of CD133 expression cells in vitro.

Wang J, Li F, Zhang G, Chen Y, Hu Y, Chen X, Lu B, Zhang X.

Hybridoma (Larchmt). 2010 Jun;29(3):241-9. doi: 10.1089/hyb.2009.0113.


Biological and genetic characteristics of tumor-initiating cells in colon cancer.

Ieta K, Tanaka F, Haraguchi N, Kita Y, Sakashita H, Mimori K, Matsumoto T, Inoue H, Kuwano H, Mori M.

Ann Surg Oncol. 2008 Feb;15(2):638-48. Epub 2007 Oct 12.


Quantitative analyses of CD133 expression facilitate researches on tumor stem cells.

Liao Y, Hu X, Huang X, He C.

Biol Pharm Bull. 2010;33(5):738-42.


Highly enriched CD133(+)CD44(+) stem-like cells with CD133(+)CD44(high) metastatic subset in HCT116 colon cancer cells.

Chen KL, Pan F, Jiang H, Chen JF, Pei L, Xie FW, Liang HJ.

Clin Exp Metastasis. 2011 Dec;28(8):751-63. doi: 10.1007/s10585-011-9407-7. Epub 2011 Jul 13.


CD133 protein N-glycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope.

Mak AB, Blakely KM, Williams RA, PenttilÀ PA, Shukalyuk AI, Osman KT, Kasimer D, Ketela T, Moffat J.

J Biol Chem. 2011 Nov 25;286(47):41046-56. doi: 10.1074/jbc.M111.261545. Epub 2011 Sep 21.


Identification of Endothelin-1 and NR4A2 as CD133-regulated genes in colon cancer cells.

Puglisi MA, Barba M, Corbi M, Errico MF, Giorda E, Saulnier N, Boninsegna A, Piscaglia AC, Carsetti R, Cittadini A, Gasbarrini A, Sgambato A.

J Pathol. 2011 Oct;225(2):305-14. doi: 10.1002/path.2954. Epub 2011 Aug 8.


The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer.

Horst D, Scheel SK, Liebmann S, Neumann J, Maatz S, Kirchner T, Jung A.

J Pathol. 2009 Dec;219(4):427-34. doi: 10.1002/path.2597.


CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116.

Dittfeld C, Dietrich A, Peickert S, Hering S, Baumann M, Grade M, Ried T, Kunz-Schughart LA.

Radiother Oncol. 2009 Sep;92(3):353-61. doi: 10.1016/j.radonc.2009.06.034. Epub 2009 Aug 21.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk